Prevalence, determinants and co-morbidities of chronic kidney disease among First Nations adults with diabetes: results from the CIRCLE study

BMC Nephrology

Stewart B Harris²  Mariam Naqshbandi Hayward²  Roland F Dyck¹ 

[1] Department of Community Health and Epidemiology, University of Saskatchewan, Saskatoon, SK, S7N 5E5, Canada;Centre for Studies in Family Medicine, Department of Family Medicine, The University of Western Ontario, London, Ontario, N6G 4X8, Canada

关键词: Risk factors.;    End stage renal disease;    Chronic kidney disease;    Diabetes;    First Nations;    Aboriginal;    Indigenous peoples;   

Others  :  1083156
DOI  :  10.1186/1471-2369-13-57

 received in 2012-03-29, accepted in 2012-06-18,  发布年份 2012

【 摘 要 】

Background

Indigenous peoples worldwide are experiencing elevated rates of type 2 diabetes and its complications. To better understand the disproportionate burden of diabetic end stage renal disease (ESRD) among Canadian First Nations people (FN), we examined prevalence, determinants, and co-morbidities of chronic kidney disease (CKD) within this population.

Methods

The 2007 Canadian FN Diabetes Clinical Management and Epidemiologic (CIRCLE) study conducted a cross-sectional national medical chart audit of 885 FN adults with type 2 diabetes to assess quality of diabetes care. In this sub-study, participants were divided by estimated glomerular filtration rate (eGFR in ml/min/1.73 m²), as well as by albuminuria level in those with eGFRs = > 60. Those with eGFRs = > 60 and negative albuminuria were considered to have normal/near normal kidney function (non-CKD). Using univariate and logistic regression analysis, they were compared with participants having eGFRs = > 60 plus albuminuria (CKD-alb) and with participants having eGFRs <60 (CKD-eGFR <60).

Results

While 84.5% of total CIRCLE participants had eGFRs = > 60, almost 60% of the latter had CKD-alb. Of the 15.5% of total participants with CKD-eGFR <60, 80% had eGFRs 30–60 (Stage 3 CKD) but over 10% (1.6% of total participants) had ESRD. Independent determinants of CKD-alb were male gender and increasing diabetes duration, systolic BP, A1C and total cholesterol. These plus smoking rates also discriminated between FN with micro- and macro-albuminuria. Independent determinants of CKD-eGFR <60 were increasing age at diabetes diagnosis, diabetes duration, total cholesterol and systolic BP. However, participants with CKD-eGFR <60 also displayed a decreasing mean age of diabetes diagnosis as eGFR declined. Micro-vascular co-morbidities were significantly associated with CKD-alb but both micro- and macro-vascular co-morbidities were associated with CKD-eGFR <60. Only 35-40% of participants with CKD used insulin.

Conclusions

High prevalences of CKD-alb and early CKD-eGFR <60 among diabetic FN were largely related to modifiable and treatable risk factors. However, an earlier age of diabetes diagnosis and longer duration of diabetes characterized those with ESRD. These findings suggest that a failure to meet current standards of diabetes care interacting with an age-related survival benefit contribute to the disproportionate burden of ESRD among FN and possibly other Indigenous peoples.

【 授权许可】

   
2012 Dyck et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Burrows NR, Narva AS, Geiss LS, Engelgau MM, Acton KJ: End-stage renal disease due to diabetes among southwestern American Indians, 1990–2001. Diabetes Care 2005, 28(5):1041-1044.
• [2]Naqshbandi M, Harris SB, Esler JG, Antwi-Nsiah F: Global complication rates of type 2 diabetes in Indigenous peoples: A comprehensive review. Diabetes Res Clin Pract 2008, 82:1-17.
• [3]Dyck RF, Osgood ND, Lin TH, Gao A, Stang MR: End-stage renal disease in people with diabetes: A comparison of First Nations people and other Saskatchewan residents from 1981–2005. Can J Diab 2010, 34(4):324-333.
• [4]Dyck RF, Osgood N, Lin TH, Gao A, Stang MR: Epidemiology of diabetes mellitus among First Nations and non-First Nations adults. Can Med Assoc J 2010, 182(3):249-256.
• [5]Hanley AJG, Harris SB, Mamakeesick M, Goodwin K, Fiddler E, Hegele RA, Spence JD, House AA, Brown ED, Schoales B, McLaughlin JR, Klein R, Zinman B: Complications of type 2 diabetes among Aboriginal Canadians. Diabetes Care 2005, 28(8):2054-2057.
• [6]Dyck RF, Sidhu N, Klomp H, Cascagnette PJ, Teare GF: Differences in Glycemic Control and Survival Predict Higher ESRD Rates in Diabetic First Nations Adults. Clin Invest Med 2010, 33(6):E390-E397.
• [7]Maple-Brown LJ, Cunningham J, Hodge AM, Weeramanthri T, Dunbar T, Lawton PD, Zimmet PZ, Chadban SJ, Polkinghorne KR, Shaw JE, O'Dea K: High rates of albuminuria but not of low eGFR in urban indigenous Australians: the DRUID study. BMC Publ Health 2011, 19(11):346. BioMed Central Full Text
• [8]Gao S, Manns BJ, Culleton BF, Tonelli M, Quan H, Crowshoe L, Ghali WA, Svenson LW, Hemmelgarn BR: for the Alberta Kidney Disease Network: Prevalence of chronic kidney disease and survival among Aboriginal people. J Am Soc Nephrol 2007, 18:2953-2959.
• [9]Pavkov ME, Bennett PH, Knowler WC, Krakov J, Seivers ML, Nelson RG: Effect of youth-onset type 2 diabetes mellitus on end-stage renal disease and mortality in young and middle-aged Pima Indians. JAMA 2010, 296(4):421-426.
• [10]Dyck RF, Tan L: Rates and outcomes of diabetic end-stage renal disease among registered native people in Saskatchewan. Can Med Assoc J 1994, 150:203-208.
• [11]Canadian Institute for Health information: 2007 Annual Report – Treatment of end stage organ failure in Canada, 1996 to 2005. Ottawa, CIHI; 2008.
• [12]Harris SB, Naqshbandi M, Bhattacharyya O, Hanley AJG, Zinman B, CIRCLE Study Group: Major gaps in diabetes clinical care among Canada’s First Nations: Results of the CIRCLE Study. Diabetes Res Clin Pract 2011, 92:272-279.
• [13]First Nations Centre: OCAP: Ownership, control, access and possession. National Aboriginal Health Organization, Ottawa, ON; 2007. http://www.naho.ca/firstnations/english/ documents/FNC-OCAP_001.pdf webcite (originally accessed October 28, 2010
• [14]Canadian Diabetes Association Clinical Practice Guidelines Expert Committee: Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008, 32(Supplement 1):S1-S201.
• [15]Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999, 130:461-70.
• [16]Nelson RG, Greene T, Beck GJ: Estimating GFR by the MDRD and Cockcroft-Gault equations in Pima Indians (abstract). J Am Soc Nephrol 2003, 14:134a.
• [17]National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39(Suppl 1):S1-S266.
• [18]Jolly SE, Mete M, Wang H, Zhu JH, Ebbesson SOE, Voruganti S, Comuzzie AG, Howard BV, Umans JG: Uric acid, hypertension, and chronic kidney disease among Alaska Eskimos: the genetics of coronary artery disease in Alaska Natives (GOCADAN) Study. J Clin Hypertens 2012, 14(2):71-77.
• [19]Whaley-Connell AT, Sowers JR, McFarlane SI, Norris KC, Chen SC, Li S, Qiu Y, Wang C, Stevens LA, Vassalotti JA, Collins AJ, Kidney Early Evaluation Program Investigators: Diabetes mellitus in CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition and Examination Survey (NHANES) 1999–2004. Am J Kidney Dis 2008, 51((4)Suppl 2):S21-S29.
• [20]Shara NM, Wang H, Valaitis E, Pehlivanova M, Carter EA, Resnick HE, Wang W, Umans JG, Lee ET, Howard BV, Devereux RB, Wilson PWF: Comparison of Estimated Glomerular Filtration Rates and Albuminuria in Predicting Risk of Coronary Heart Disease in a Population with High Prevalence of Diabetes Mellitus and Renal Disease. Am J Cardiol 2011, 107(3):399-405.
• [21]Oster RT, Johnson JA, Hemmelgarn BR, King M, Balko SU, Svenson LW, Crowshoe L, Toth EL: Recent epidemiologic trends of diabetes mellitus among status Aboriginal adults. Can Med Assoc 2011, 183(12):E803-E808.
• [22]Shurraw S, Hemmelgarn B, Lin M, Majumdar SR, Klarenbach S, Manns B, Bello A, James M, Chowdhury Turin T, Tonelli M: for the Alberta Kidney Disease Network: Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease. Arch Intern Med 2011, 171(21):1920-1927.
• [23]The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med 1993, 329:977-986.
• [24]Bash LD, Selvin E, Steffes M, Coresh J, Astor BC: Poor glycemic control in diabetes and the risk of incident chronic kidney disease even in the absence of albuminuria and retinopathy – Atherosclerosis Risk in Communities (ARIC) Study. Arch Intern Med 2008, 168(22):2440-2447.
• [25]Gaede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383-393.
• [26]Harris SB, Zinman B, Hanley A, Gittelsohn J, Hegele R, Connelly PW, Shah B, Hux JE: The impact of diabetes on cardiovascular risk factors and outcomes in a native Canadian population. Diabetes Res Clin Pract 2002, 55(2):165-173.
• [27]Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW: Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003, 108:2154-2169.
• [28]Di Angelantonio E, Chowdhury R, Sarwar N, Aspelund T, Danesh J, Gudnason V: Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study. BMJ 2010, 341:c4986.
• [29]Klomp H, Dyck RF, Sidhu N, Cascagnette PJ, Teare GF: Measuring Quality of Diabetes Care by Linking Health Care System Administrative Databases with Laboratory Data. BMC Research Notes 2010, 3(233):8. www.biomedcentral.com/1756-0500/3/233 webcite
• [30]Stevens LA, Coresh J, Greene T, Levey AS: Assessing Kidney Function - Measured and Estimated Glomerular Filtration Rate. N Engl J Med 2006, 354(23):2473-2483.
• [31]Glassock RJ, Winearls CG: eGFR: Readjusting its rating. Clin J Am Soc Nephrol 2009, 4(5):867-869.
• [32]Hallan SI, Orth SR: The KDOQI 2002 classification of chronic kidney disease: for whom the bell tolls. Nephrol Dial Transplant 2010.
• [33]Dyck RF, Bohm CJ, Klomp H: Increased frequency of HLA A2/DR4 and A2/DR8 haplotypes in young Saskatchewan Aboriginal people with diabetic end stage renal disease. Am J Neph 2003, 23(3):178-185.
• [34]Imperatore G, Knowler WC, Nelson RG, Hanson RL: Genetics of diabetic nephropathy in the Pima Indians. Curr Diab Rep 2001, 1(3):275-81.
• [35]Nelson RG, Morgenstern H, Bennett PH: Intrauterine diabetes exposure and the risk of renal disease in diabetic Pima Indians. Diabetes 1998, 47:1489-1493.
• [36]Macaulay AC, Paradis G, Potvin L, Cross EJ, Saad-Haddad C, McComber A, Serge Desrosiers , Kirby R, Montour LT, Lamping DL, Leduc N, Rivard M: The Kahnawake Schools Diabetes Prevention Project: intervention, evaluation and baseline results of a diabetes primary prevention program with a Native community in Canada. Prev Med 1997, 26:779-90.
• [37]Gittelsohn J, Harris SB, Whitehead S, Wolever TMS, Hanley JG, Barnie A, Kakegamic L, Logan A, Zinman B: Developing diabetes interventions in an Ojibwa-Cree community in northern Ontario: Linking qualitative and quantitative data. Chronic Dis Can 1995, 16:157-64.